MCL1 and hepatocellular carcinoma: Moreover, increased BCL-xL and the BCL-xL/MCL-1 ratio are exhibited by patients with HCC, with predicted worse prognosis, suggesting that A-1331852 could be an interesting drug to combine with regorafenib during therapy.